Navigation Links
BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:10/31/2008

ion or $0.32 per share.

As of September 30, 2008, the Company held cash, cash equivalents and investments of $67.9 million.

Year-to-Date 2008 Financial Results

Collaborative and other research and development revenues were $22.3 million for the nine months ended September 30, 2008, compared to $43.1 million for the nine months ended September 30, 2007. This decrease is driven by a reduction in peramivir related clinical development costs leading to a reduction in costs and associated revenue from HHS, plus the $4.9 million reserve taken in the second quarter of 2008 for amounts BioCryst previously expected to receive from HHS related to costs incurred in the Phase 3 program in intramuscular peramivir for outpatient influenza. These costs were associated with the Phase 3 program for peramivir that was voluntarily discontinued earlier this year and reimbursement of these costs is under discussion with HHS.

R&D expenses were $51.3 million for the nine months ended September 30, 2008, compared to $64.9 million for the nine months ended September 30, 2007. The decrease in R&D expenses is due to a reduction in the clinical development costs and toxicology costs associated with the peramivir program and a reduction in manufacturing costs associated with both the peramivir and forodesine HCl programs. These reductions were partially offset by an increase in the Company's clinical development costs for forodesine HCl and increases in personnel related costs and professional services.

G&A expenses were $8.0 million for the nine months ended September 30, 2008, compared to $7.0 million for the nine months ended September 30, 2007. The higher expenses were primarily due to an increase in professional fees and personnel related costs.

The net loss for the nine months ended September 30, 2008 was $34.8 million, or $0.91 per share, compared to a net loss for the nine months ended September 30, 2007 of $26.8 million or $0.86 per share.


'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
2. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
3. BioCryst to Present at the JMP Healthcare Focus Conference
4. BioCryst to Present at UBS 2008 Global Life Sciences Conference
5. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
6. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
9. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
10. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
11. BioCryst to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... August 22, 2014 “Our nation's ... is a national disgrace. Furthermore, every governmental and ... the current, deplorable state of unorganized dysfunction shares ... mistakes," to merely serve as a device to ... of colossal failure(s) that have accumulated through the ...
(Date:8/21/2014)...  BioSpecifics Technologies Corp. (NASDAQ: BSTC ... collagenase-based products marketed as XIAFLEX ® (collagenase ... XIAPEX ® in the EU, today announced ... Phase 2a study of CCH for the potential ... results showed that all three doses of CCH ...
(Date:8/21/2014)... Rockville, MD (PRWEB) August 21, 2014 ... is making progress in its development of JRC-LAMP-vax, an ... red cedar pollen. Phase IC studies began this month ... solution to hay fever. , The Japanese red cedar ... million people in Japan. Mountain Cedar pollen wreaks similar ...
(Date:8/21/2014)... group at the Institute for Molecular Medicine Finland ... has developed a novel "man and machine" decision ... diagnostic aid was described in PLOS One ... is based on computer vision algorithms similar to ... visualization of only the diagnostically most relevant areas. ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4A novel 'man and machine' decision support system makes malaria diagnostics more effective 2
... in German . , The polymer ... expected about 30 scientists to attend the kick-off meeting ... for Carbon-based Nanocomposites). New kinds of plastic-based nanocomposites could ... the mechanical stability of materials and add electrical or ...
... a Rochester, NY company today announced it is bringing aboard Ashton ... to head up global sales and marketing. , ... ... company today announced it is bringing aboard Ashton S. Maaraba, a ...
... a biopharmaceutical company specializing in the research and,development of ... reported financial results for the three and twelve months,ended ... in Canadian,dollars., 2008 HIGHLIGHTS, - ... anticancer small molecule drug ...
Cached Biology Technology:Using nanotechnology to create high-performance materials 2Pharmasmart International Taps Top Executive Ashton Maaraba to Head Global Sales and Marketing 2Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 2Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 3Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 4Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 5Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 6Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 7Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 8
(Date:8/22/2014)... be able to purchase fuel cell cars from Toyota ... of the cars will run on hydrogen made from ... warming. , Now scientists at Stanford University have developed ... battery to produce hydrogen by water electrolysis. The ... split liquid water into hydrogen and oxygen gas. Unlike ...
(Date:8/22/2014)... the bees. But that old expression leaves out ... process for flowering plants is particularly complex and ... reproductive cells. New research from an international team ... Carnegie,s Wolf Frommer, David Ehrhardt, and Guido Grossmann ... guides flowering plant fertilization. It is published in ...
(Date:8/21/2014)... international team of scientists including researchers from the University of ... known as canolain the journal Science . Their discovery ... is used widely in farming and industry. , Canola ... but the winter crop is increasingly cultivated in Georgia. Canola ... levels of saturated fat and rich supply of omega-3 fatty ...
Breaking Biology News(10 mins):Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3Calcium and reproduction go together 2Canola genome sequence reveals evolutionary 'love triangle' 2
... Since the smoking ban in restaurants, bars and ... as body odors and the smell of old beer, ... science is looking at how the introduction of pleasant ... nightlife experience. According to Dr. Hendrik Schifferstein from Delft ...
... River and its tributaries, is the largest contiguous wetland in ... it is an ark for large populations of species that ... large range of ecosystem services that are essential for humanity. ... plants, animals, and local human populations show an impressive range ...
... organ-on-a-chip devices that mimic the way real organs work, ... of therapies more accurately, will be discussed by a ... Professor Don Ingber, Director of the Wyss ... deliver the inaugural Bagrit Lecture, which will be held ...
Cached Biology News:Clubbers can smell a good nightspot 2Media invitation: Pioneer of organ-on-a-chip technology to speak at Imperial College London 2
...
... camera controller is the successor to the original ... any of the cameras in the Nikon DS ... USB2.0 interface. The DS-U2 transmits information at high ... equipping both hub and mass storage USB 2.0 ...
This unique buffer provides a gentle method for removal of primary and secondary antibodies to allow several reprobings on the same membrane. Gentle buffer will not alter the antigen for subsequent i...
...
Biology Products: